Sporanox to be avoided in heart failure

The antifungal agent Sporanox (itraconazole) should not be used in patients with congestive heart failure or a history of congestive heart failure unless the benefit clearly outweighs the risk.

The warning follows observations that Sporanox exerts a negative inotropic effect, and reports of congestive heart failure associated with its use.

If the benefits do exceed the risk of using Sporanox in patients with heart failure, such patients should be monitored closely and the drug discontinued if symptoms of heart failure develop.

View Sporanox drug record

Further Information: Janssen-Cilag Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

'Innovative' heart failure treatment recommended by NICE

'Innovative' heart failure treatment recommended by NICE

Dapagliflozin (Forxiga), the first SGLT2 inhibitor...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregabalin linked to severe respiratory depression in absence of opioids

Pregabalin linked to severe respiratory depression in absence of opioids

The MHRA advises prescribers to consider adjustment...